B‐cell repopulation dynamics and drug pharmacokinetics impact <scp>SARS‐CoV</scp>‐2 vaccine efficacy in <scp>anti‐CD20</scp>‐treated multiple sclerosis patients

Abstract

These findings are relevant for providing individualized guidance to patients and planning of vaccination schemes, in turn optimizing benefit-risk with anti-CD20.